Beyond the Lab: Clinical Trials

Dear readers,

Welcome to our latest report on the evolving landscape of clinical trials in drug discovery. In these pages, we spotlight the most recent breakthroughs that are reshaping the field and explore how cutting-edge technologies are facilitating more precise, efficient and cost-effective approaches to drug development.

From the integration of biomarkers and AI to optimise patient selection and trial design, to smarter financial management tools and streamlined logistics for advanced therapies, the industry is increasingly embracing data-driven strategies to improve success rates and accelerate the delivery of life-changing treatments.

You’ll also learn how interactive response technology (IRT) is transforming the management of cell and gene therapy (CGT) trials, and why robust financial planning and oversight are crucial to ensuring clinical trial success.

Plus, find out how clinical genomics and AI are reshaping drug development by enhancing target identification, patient stratification and trial design. 

Featured experts:

• Dr Russ Lebovitz – CEO of Amprion
• Cara Woodruff – Director of Product Management at IQVIA IRT
• Jennifer Kyle – Founder and CEO of Condor Software 
• Dr Cyril Clarke – Vice President of ICON Biotech
• Dr Remco Jan Geukes Foppen – Consultant at Regina Elena National Cancer Institute
• Vincenzo Gioia – AI Transition Manager – Independent Researcher
• Dr Carlos N Velez – Managing Partner at Lacerta Bio Inc.
• Alessio Zoccoli – Senior Data Scientist – Independent Researcher.

We hope you find this report insightful, informative, and a valuable resource as you navigate the future of clinical innovation. 

Sincerely,

Dr Carrie Haslam

Editor

Drug Target Review